12-10-2011
Dr. Ashraf Shaalan, Chairman of the National Center for Research on the start of the first stages of the manufacture of flu vaccine bird of Egypt with a capacity of half a billion doses, in collaboration with an Egyptian company specialized in the manufacture of vaccines, pointing out that the vaccine product depends on the findings of the research team at the Centre.
In a statement to the Middle East News Agency today, Shaalan said that the vaccine strains isolated from the latest avian influenza virus in Egypt is currently using genetic engineering, to ensure effectiveness in the prevention of the virus up to double the effectiveness of the vaccine importer.
He added that the announcement of more details on this topic during the coming period.
No comments:
Post a Comment